Proteome Sciences Statement re Share Price Movement

Statement re Share Price Movement

5th February 2008

The Board of Proteome Sciences has noted the recent movement in the Company’s share price and that they are not aware of any reason for the share price increase.

In the trading update released on 21 December 2007, the Board reported that it continued to view future prospects for TMT® commercialisation with increasing confidence, with the related licence negotiations expected to be concluded in early 2008. This remains the case and the Company will issue a further update on licence negotiations in due course.

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.